市場調査レポート
商品コード
1064417

強皮症治療の世界市場:2022年~2026年

Global Scleroderma Therapeutics Market 2022-2026

出版日: | 発行: TechNavio (Infiniti Research Ltd.) | ページ情報: 英文 120 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=135.61円
強皮症治療の世界市場:2022年~2026年
出版日: 2022年03月02日
発行: TechNavio (Infiniti Research Ltd.)
ページ情報: 英文 120 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界の強皮症治療の市場規模は、2022年から2026年の間に5億7,387万米ドル成長し、予測期間中は5.44%のCAGRで成長する見込みです。

この市場は、アンメットメディカルニーズの高さ、意識向上のための取り組みの高まり、R&D活動への資金増加によって牽引されています。

当レポートでは、強皮症治療の世界市場の全体的な分析、市場規模と予測、動向、成長促進要因、課題、および約25のベンダーをカバーする分析を提供しています。

目次

第1章 エグゼクティブサマリー

  • 市場概要

第2章 市場情勢

  • 市場のエコシステム

第3章 市場規模

  • 市場の定義
  • 市場セグメント分析
  • 2021年の市場規模
  • 市場の見通し:2021年から2026年の予測

第4章 ファイブフォース分析

  • ファイブフォースまとめ
  • 買い手の交渉力
  • 供給企業の交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • 競争の脅威
  • 市況

第5章 市場セグメンテーション:疾患タイプ別

  • 市場セグメント
  • 疾患タイプ別比較
  • 局所性強皮症:市場規模と予測(2021年~2026年)
  • 全身性強皮症:市場規模と予測(2021年~2026年)
  • 疾患タイプ別の市場機会

第6章 顧客情勢

  • 顧客情勢の概要

第7章 地域別情勢

  • 地域別セグメンテーション
  • 地域別の比較
  • 北米:市場規模と予測(2021年~2026年)
  • 欧州:市場規模と予測(2021年~2026年)
  • アジア:市場規模と予測(2021年~2026年)
  • その他の地域(ROW):市場規模と予測(2021年~2026年)
  • カナダ:市場規模と予測(2021年~2026年)
  • 米国:市場規模と予測(2021年~2026年)
  • デンマーク:市場規模と予測(2021年~2026年)
  • 中国:市場規模と予測(2021年~2026年)
  • インド:市場規模と予測(2021年~2026年)
  • 地域情勢別の市場機会

第8章 推進要因、課題、動向

  • 市場推進要因
  • 市場の課題
  • 推進要因と課題の影響
  • 市場動向

第9章 ベンダー情勢

  • 概要
  • ベンダー情勢
  • 混乱の状況
  • 業界のリスク

第10章 ベンダー分析

  • 対象ベンダー
  • ベンダーの市場ポジショニング
  • Akashi Therapeutics
  • Argentis Pharmaceuticals LLC
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co.
  • Castle Creek Biosciences Inc.
  • Chemomab Therapeutics Ltd.
  • Corbus Pharmaceuticals Holdings Inc.
  • Emerald Health Pharmaceuticals
  • F. Hoffmann La Roche Ltd.
  • Kadmon Holdings Inc.

第11章 付録

  • 調査範囲
  • 包含と除外のチェックリスト
  • US$の為替レート
  • 調査手法
  • 略語のリスト
目次
Product Code: IRTNTR72388

Technavio has been monitoring the scleroderma therapeutics market and it is poised to grow by $ 573.87 mn during 2022-2026, progressing at a CAGR of 5.44% during the forecast period. Our report on the scleroderma therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by high unmet medical needs, rising focus on awareness-raising initiatives, and increased funding for R and D activities. In addition, high unmet medical needs are anticipated to boost the growth of the market as well.

The scleroderma therapeutics market analysis includes disease segment and geographic landscape.

Technavio's scleroderma therapeutics market is segmented as below:

By Disease Type

  • Localized Scleroderma
  • Systemic Scleroderma

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)

This study identifies the introduction of stem cell therapy in scleroderma treatment as one of the prime reasons driving the scleroderma therapeutics market growth during the next few years. Also, the advent of novel therapies, partnerships, and strategic alliances will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the scleroderma therapeutics market covers the following areas:

  • Scleroderma therapeutics market sizing
  • Scleroderma therapeutics market forecast
  • Scleroderma therapeutics market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading scleroderma therapeutics market vendors that include AbbVie Inc., Akashi Therapeutics, Amneal Pharmaceuticals Inc., Antares Pharma Inc., Argentis Pharmaceuticals LLC, AstraZeneca Plc, Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., Castle Creek Biosciences Inc., Chemomab Therapeutics Ltd., Corbus Pharmaceuticals Holdings Inc., Cumberland Pharmaceuticals Inc., Emerald Health Pharmaceuticals, F. Hoffmann La Roche Ltd., Kadmon Holdings Inc., Medexus Pharmaceuticals Inc., Novartis AG, Pfizer Inc., and The Procter and Gamble Co. Also, the scleroderma therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

  • 1.1 Market overview
  • Exhibit 01: Executive Summary - Chart on Market Overview
  • Exhibit 02: Executive Summary - Data Table on Market Overview
  • Exhibit 03: Executive Summary - Chart on Global Market Characteristics
  • Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
  • Exhibit 05: Executive Summary - Chart on Market Segmentation by Disease Type
  • Exhibit 06: Executive Summary - Chart on Incremental Growth
  • Exhibit 07: Executive Summary - Data Table on Incremental Growth
  • Exhibit 08: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
  • Exhibit 09: Parent market
  • Exhibit 10: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
  • Exhibit 11: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
  • Exhibit 12: Market segments
  • 3.3 Market size 2021
  • 3.4 Market outlook: Forecast for 2021-2026
  • Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
  • Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
  • Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
  • Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

  • 4.1 Five forces summary
  • Exhibit 17: Five forces analysis - Comparison between 2021 and 2026
  • 4.2 Bargaining power of buyers
  • Exhibit 18: Bargaining power of buyers - Impact of key factors in 2021 and 2026
  • 4.3 Bargaining power of suppliers
  • Exhibit 19: Bargaining power of suppliers - Impact of key factors in 2021 and 2026
  • 4.4 Threat of new entrants
  • Exhibit 20: Threat of new entrants - Impact of key factors in 2021 and 2026
  • 4.5 Threat of substitutes
  • Exhibit 21: Threat of substitutes - Impact of key factors in 2021 and 2026
  • 4.6 Threat of rivalry
  • Exhibit 22: Threat of rivalry - Impact of key factors in 2021 and 2026
  • 4.7 Market condition
  • Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

5 Market Segmentation by Disease Type

  • 5.1 Market segments
  • Exhibit 24: Chart on Disease Type - Market share 2021-2026 (%)
  • Exhibit 25: Data Table on Disease Type - Market share 2021-2026 (%)
  • 5.2 Comparison by Disease Type
  • Exhibit 26: Chart on Comparison by Disease Type
  • Exhibit 27: Data Table on Comparison by Disease Type
  • 5.3 Localized scleroderma - Market size and forecast 2021-2026
  • Exhibit 28: Chart on Localized scleroderma - Market size and forecast 2021-2026 ($ million)
  • Exhibit 29: Data Table on Localized scleroderma - Market size and forecast 2021-2026 ($ million)
  • Exhibit 30: Chart on Localized scleroderma - Year-over-year growth 2021-2026 (%)
  • Exhibit 31: Data Table on Localized scleroderma - Year-over-year growth 2021-2026 (%)
  • 5.4 Systemic scleroderma - Market size and forecast 2021-2026
  • Exhibit 32: Chart on Systemic scleroderma - Market size and forecast 2021-2026 ($ million)
  • Exhibit 33: Data Table on Systemic scleroderma - Market size and forecast 2021-2026 ($ million)
  • Exhibit 34: Chart on Systemic scleroderma - Year-over-year growth 2021-2026 (%)
  • Exhibit 35: Data Table on Systemic scleroderma - Year-over-year growth 2021-2026 (%)
  • 5.5 Market opportunity by Disease Type
  • Exhibit 36: Market opportunity by Disease Type ($ million)

6 Customer Landscape

  • 6.1 Customer landscape overview
  • Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

  • 7.1 Geographic segmentation
  • Exhibit 38: Chart on Market share By Geographical Landscape 2021-2026 (%)
  • Exhibit 39: Data Table on Market share By Geographical Landscape 2021-2026 (%)
  • 7.2 Geographic comparison
  • Exhibit 40: Chart on Geographic comparison
  • Exhibit 41: Data Table on Geographic comparison
  • 7.3 North America - Market size and forecast 2021-2026
  • Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million)
  • Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
  • Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%)
  • Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%)
  • 7.4 Europe - Market size and forecast 2021-2026
  • Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
  • Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
  • Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%)
  • Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%)
  • 7.5 Asia - Market size and forecast 2021-2026
  • Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
  • Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
  • Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%)
  • Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%)
  • 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
  • Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
  • Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
  • Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
  • Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
  • 7.7 Canada - Market size and forecast 2021-2026
  • Exhibit 58: Chart on Canada - Market size and forecast 2021-2026 ($ million)
  • Exhibit 59: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
  • Exhibit 60: Chart on Canada - Year-over-year growth 2021-2026 (%)
  • Exhibit 61: Data Table on Canada - Year-over-year growth 2021-2026 (%)
  • 7.8 US - Market size and forecast 2021-2026
  • Exhibit 62: Chart on US - Market size and forecast 2021-2026 ($ million)
  • Exhibit 63: Data Table on US - Market size and forecast 2021-2026 ($ million)
  • Exhibit 64: Chart on US - Year-over-year growth 2021-2026 (%)
  • Exhibit 65: Data Table on US - Year-over-year growth 2021-2026 (%)
  • 7.9 Denmark - Market size and forecast 2021-2026
  • Exhibit 66: Chart on Denmark - Market size and forecast 2021-2026 ($ million)
  • Exhibit 67: Data Table on Denmark - Market size and forecast 2021-2026 ($ million)
  • Exhibit 68: Chart on Denmark - Year-over-year growth 2021-2026 (%)
  • Exhibit 69: Data Table on Denmark - Year-over-year growth 2021-2026 (%)
  • 7.10 China - Market size and forecast 2021-2026
  • Exhibit 70: Chart on China - Market size and forecast 2021-2026 ($ million)
  • Exhibit 71: Data Table on China - Market size and forecast 2021-2026 ($ million)
  • Exhibit 72: Chart on China - Year-over-year growth 2021-2026 (%)
  • Exhibit 73: Data Table on China - Year-over-year growth 2021-2026 (%)
  • 7.11 India - Market size and forecast 2021-2026
  • Exhibit 74: Chart on India - Market size and forecast 2021-2026 ($ million)
  • Exhibit 75: Data Table on India - Market size and forecast 2021-2026 ($ million)
  • Exhibit 76: Chart on India - Year-over-year growth 2021-2026 (%)
  • Exhibit 77: Data Table on India - Year-over-year growth 2021-2026 (%)
  • 7.12 Market opportunity By Geographical Landscape
  • Exhibit 78: Market opportunity By Geographical Landscape ($ million)

8 Drivers, Challenges, and Trends

  • 8.1 Market drivers
  • 8.2 Market challenges
  • 8.3 Impact of drivers and challenges
  • Exhibit 79: Impact of drivers and challenges in 2021 and 2026
  • 8.4 Market trends

9 Vendor Landscape

  • 9.1 Overview
  • 9.2 Vendor landscape
  • Exhibit 80: Overview on Criticality of inputs and Factors of differentiation
  • 9.3 Landscape disruption
  • Exhibit 81: Overview on factors of disruption
  • 9.4 Industry risks
  • Exhibit 82: Impact of key risks on business

10 Vendor Analysis

  • 10.1 Vendors covered
  • Exhibit 83: Vendors covered
  • 10.2 Market positioning of vendors
  • Exhibit 84: Matrix on vendor position and classification
  • 10.3 Akashi Therapeutics
  • Exhibit 85: Akashi Therapeutics - Overview
  • Exhibit 86: Akashi Therapeutics - Product / Service
  • Exhibit 87: Akashi Therapeutics - Key offerings
  • 10.4 Argentis Pharmaceuticals LLC
  • Exhibit 88: Argentis Pharmaceuticals LLC - Overview
  • Exhibit 89: Argentis Pharmaceuticals LLC - Product / Service
  • Exhibit 90: Argentis Pharmaceuticals LLC - Key offerings
  • 10.5 Boehringer Ingelheim International GmbH
  • Exhibit 91: Boehringer Ingelheim International GmbH - Overview
  • Exhibit 92: Boehringer Ingelheim International GmbH - Business segments
  • Exhibit 93: Boehringer Ingelheim International GmbH - Key news
  • Exhibit 94: Boehringer Ingelheim International GmbH - Key offerings
  • Exhibit 95: Boehringer Ingelheim International GmbH - Segment focus
  • 10.6 Bristol-Myers Squibb Co.
  • Exhibit 96: Bristol-Myers Squibb Co. - Overview
  • Exhibit 97: Bristol-Myers Squibb Co. - Product / Service
  • Exhibit 98: Bristol-Myers Squibb Co. - Key offerings
  • 10.7 Castle Creek Biosciences Inc.
  • Exhibit 99: Castle Creek Biosciences Inc. - Overview
  • Exhibit 100: Castle Creek Biosciences Inc. - Product / Service
  • Exhibit 101: Castle Creek Biosciences Inc. - Key offerings
  • 10.8 Chemomab Therapeutics Ltd.
  • Exhibit 102: Chemomab Therapeutics Ltd. - Overview
  • Exhibit 103: Chemomab Therapeutics Ltd. - Business segments
  • Exhibit 104: Chemomab Therapeutics Ltd. - Key offerings
  • Exhibit 105: Chemomab Therapeutics Ltd. - Segment focus
  • 10.9 Corbus Pharmaceuticals Holdings Inc.
  • Exhibit 106: Corbus Pharmaceuticals Holdings Inc. - Overview
  • Exhibit 107: Corbus Pharmaceuticals Holdings Inc. - Business segments
  • Exhibit 108: Corbus Pharmaceuticals Holdings Inc. - Key offerings
  • Exhibit 109: Corbus Pharmaceuticals Holdings Inc. - Segment focus
  • 10.10 Emerald Health Pharmaceuticals
  • Exhibit 110: Emerald Health Pharmaceuticals - Overview
  • Exhibit 111: Emerald Health Pharmaceuticals - Business segments
  • Exhibit 112: Emerald Health Pharmaceuticals - Key offerings
  • Exhibit 113: Emerald Health Pharmaceuticals - Segment focus
  • 10.11 F. Hoffmann La Roche Ltd.
  • Exhibit 114: F. Hoffmann La Roche Ltd. - Overview
  • Exhibit 115: F. Hoffmann La Roche Ltd. - Business segments
  • Exhibit 116: F. Hoffmann La Roche Ltd. - Key news
  • Exhibit 117: F. Hoffmann La Roche Ltd. - Key offerings
  • Exhibit 118: F. Hoffmann La Roche Ltd. - Segment focus
  • 10.12 Kadmon Holdings Inc.
  • Exhibit 119: Kadmon Holdings Inc. - Overview
  • Exhibit 120: Kadmon Holdings Inc. - Product / Service
  • Exhibit 121: Kadmon Holdings Inc. - Key offerings

11 Appendix

  • 11.1 Scope of the report
  • 11.2 Inclusions and exclusions checklist
  • Exhibit 122: Inclusions checklist
  • Exhibit 123: Exclusions checklist
  • 11.3 Currency conversion rates for US$
  • Exhibit 124: Currency conversion rates for US$
  • 11.4 Research methodology
  • Exhibit 125: Research methodology
  • Exhibit 126: Validation techniques employed for market sizing
  • Exhibit 127: Information sources
  • 11.5 List of abbreviations
  • Exhibit 128: List of abbreviations

Exhibits

  • Exhibits1: Executive Summary - Chart on Market Overview
  • Exhibits2: Executive Summary - Data Table on Market Overview
  • Exhibits3: Executive Summary - Chart on Global Market Characteristics
  • Exhibits4: Executive Summary - Chart on Market By Geographical Landscape
  • Exhibits5: Executive Summary - Chart on Market Segmentation by Disease Type
  • Exhibits6: Executive Summary - Chart on Incremental Growth
  • Exhibits7: Executive Summary - Data Table on Incremental Growth
  • Exhibits8: Executive Summary - Chart on Vendor Market Positioning
  • Exhibits9: Parent market
  • Exhibits10: Market Characteristics
  • Exhibits11: Offerings of vendors included in the market definition
  • Exhibits12: Market segments
  • Exhibits13: Chart on Global - Market size and forecast 2021-2026 ($ million)
  • Exhibits14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
  • Exhibits15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
  • Exhibits16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)
  • Exhibits17: Five forces analysis - Comparison between 2021 and 2026
  • Exhibits18: Bargaining power of buyers - Impact of key factors in 2021 and 2026
  • Exhibits19: Bargaining power of suppliers - Impact of key factors in 2021 and 2026
  • Exhibits20: Threat of new entrants - Impact of key factors in 2021 and 2026
  • Exhibits21: Threat of substitutes - Impact of key factors in 2021 and 2026
  • Exhibits22: Threat of rivalry - Impact of key factors in 2021 and 2026
  • Exhibits23: Chart on Market condition - Five forces 2021 and 2026
  • Exhibits24: Chart on Disease Type - Market share 2021-2026 (%)
  • Exhibits25: Data Table on Disease Type - Market share 2021-2026 (%)
  • Exhibits26: Chart on Comparison by Disease Type
  • Exhibits27: Data Table on Comparison by Disease Type
  • Exhibits28: Chart on Localized scleroderma - Market size and forecast 2021-2026 ($ million)
  • Exhibits29: Data Table on Localized scleroderma - Market size and forecast 2021-2026 ($ million)
  • Exhibits30: Chart on Localized scleroderma - Year-over-year growth 2021-2026 (%)
  • Exhibits31: Data Table on Localized scleroderma - Year-over-year growth 2021-2026 (%)
  • Exhibits32: Chart on Systemic scleroderma - Market size and forecast 2021-2026 ($ million)
  • Exhibits33: Data Table on Systemic scleroderma - Market size and forecast 2021-2026 ($ million)
  • Exhibits34: Chart on Systemic scleroderma - Year-over-year growth 2021-2026 (%)
  • Exhibits35: Data Table on Systemic scleroderma - Year-over-year growth 2021-2026 (%)
  • Exhibits36: Market opportunity by Disease Type ($ million)
  • Exhibits37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Exhibits38: Chart on Market share By Geographical Landscape 2021-2026 (%)
  • Exhibits39: Data Table on Market share By Geographical Landscape 2021-2026 (%)
  • Exhibits40: Chart on Geographic comparison
  • Exhibits41: Data Table on Geographic comparison
  • Exhibits42: Chart on North America - Market size and forecast 2021-2026 ($ million)
  • Exhibits43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
  • Exhibits44: Chart on North America - Year-over-year growth 2021-2026 (%)
  • Exhibits45: Data Table on North America - Year-over-year growth 2021-2026 (%)
  • Exhibits46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
  • Exhibits47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
  • Exhibits48: Chart on Europe - Year-over-year growth 2021-2026 (%)
  • Exhibits49: Data Table on Europe - Year-over-year growth 2021-2026 (%)
  • Exhibits50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
  • Exhibits51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
  • Exhibits52: Chart on Asia - Year-over-year growth 2021-2026 (%)
  • Exhibits53: Data Table on Asia - Year-over-year growth 2021-2026 (%)
  • Exhibits54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
  • Exhibits55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
  • Exhibits56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
  • Exhibits57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
  • Exhibits58: Chart on Canada - Market size and forecast 2021-2026 ($ million)
  • Exhibits59: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
  • Exhibits60: Chart on Canada - Year-over-year growth 2021-2026 (%)
  • Exhibits61: Data Table on Canada - Year-over-year growth 2021-2026 (%)
  • Exhibits62: Chart on US - Market size and forecast 2021-2026 ($ million)
  • Exhibits63: Data Table on US - Market size and forecast 2021-2026 ($ million)
  • Exhibits64: Chart on US - Year-over-year growth 2021-2026 (%)
  • Exhibits65: Data Table on US - Year-over-year growth 2021-2026 (%)
  • Exhibits66: Chart on Denmark - Market size and forecast 2021-2026 ($ million)
  • Exhibits67: Data Table on Denmark - Market size and forecast 2021-2026 ($ million)
  • Exhibits68: Chart on Denmark - Year-over-year growth 2021-2026 (%)
  • Exhibits69: Data Table on Denmark - Year-over-year growth 2021-2026 (%)
  • Exhibits70: Chart on China - Market size and forecast 2021-2026 ($ million)
  • Exhibits71: Data Table on China - Market size and forecast 2021-2026 ($ million)
  • Exhibits72: Chart on China - Year-over-year growth 2021-2026 (%)
  • Exhibits73: Data Table on China - Year-over-year growth 2021-2026 (%)
  • Exhibits74: Chart on India - Market size and forecast 2021-2026 ($ million)
  • Exhibits75: Data Table on India - Market size and forecast 2021-2026 ($ million)
  • Exhibits76: Chart on India - Year-over-year growth 2021-2026 (%)
  • Exhibits77: Data Table on India - Year-over-year growth 2021-2026 (%)
  • Exhibits78: Market opportunity By Geographical Landscape ($ million)
  • Exhibits79: Impact of drivers and challenges in 2021 and 2026
  • Exhibits80: Overview on Criticality of inputs and Factors of differentiation
  • Exhibits81: Overview on factors of disruption
  • Exhibits82: Impact of key risks on business
  • Exhibits83: Vendors covered
  • Exhibits84: Matrix on vendor position and classification
  • Exhibits85: Akashi Therapeutics - Overview
  • Exhibits86: Akashi Therapeutics - Product / Service
  • Exhibits87: Akashi Therapeutics - Key offerings
  • Exhibits88: Argentis Pharmaceuticals LLC - Overview
  • Exhibits89: Argentis Pharmaceuticals LLC - Product / Service
  • Exhibits90: Argentis Pharmaceuticals LLC - Key offerings
  • Exhibits91: Boehringer Ingelheim International GmbH - Overview
  • Exhibits92: Boehringer Ingelheim International GmbH - Business segments
  • Exhibits93: Boehringer Ingelheim International GmbH - Key news
  • Exhibits94: Boehringer Ingelheim International GmbH - Key offerings
  • Exhibits95: Boehringer Ingelheim International GmbH - Segment focus
  • Exhibits96: Bristol-Myers Squibb Co. - Overview
  • Exhibits97: Bristol-Myers Squibb Co. - Product / Service
  • Exhibits98: Bristol-Myers Squibb Co. - Key offerings
  • Exhibits99: Castle Creek Biosciences Inc. - Overview
  • Exhibits100: Castle Creek Biosciences Inc. - Product / Service
  • Exhibits101: Castle Creek Biosciences Inc. - Key offerings
  • Exhibits102: Chemomab Therapeutics Ltd. - Overview
  • Exhibits103: Chemomab Therapeutics Ltd. - Business segments
  • Exhibits104: Chemomab Therapeutics Ltd. - Key offerings
  • Exhibits105: Chemomab Therapeutics Ltd. - Segment focus
  • Exhibits106: Corbus Pharmaceuticals Holdings Inc. - Overview
  • Exhibits107: Corbus Pharmaceuticals Holdings Inc. - Business segments
  • Exhibits108: Corbus Pharmaceuticals Holdings Inc. - Key offerings
  • Exhibits109: Corbus Pharmaceuticals Holdings Inc. - Segment focus
  • Exhibits110: Emerald Health Pharmaceuticals - Overview
  • Exhibits111: Emerald Health Pharmaceuticals - Business segments
  • Exhibits112: Emerald Health Pharmaceuticals - Key offerings
  • Exhibits113: Emerald Health Pharmaceuticals - Segment focus
  • Exhibits114: F. Hoffmann La Roche Ltd. - Overview
  • Exhibits115: F. Hoffmann La Roche Ltd. - Business segments
  • Exhibits116: F. Hoffmann La Roche Ltd. - Key news
  • Exhibits117: F. Hoffmann La Roche Ltd. - Key offerings
  • Exhibits118: F. Hoffmann La Roche Ltd. - Segment focus
  • Exhibits119: Kadmon Holdings Inc. - Overview
  • Exhibits120: Kadmon Holdings Inc. - Product / Service
  • Exhibits121: Kadmon Holdings Inc. - Key offerings
  • Exhibits122: Inclusions checklist
  • Exhibits123: Exclusions checklist
  • Exhibits124: Currency conversion rates for US$
  • Exhibits125: Research methodology
  • Exhibits126: Validation techniques employed for market sizing
  • Exhibits127: Information sources
  • Exhibits128: List of abbreviations